{"SPADE_UN_11329": {"Clinical Information": [{"Medical use": "Infected diabetic foot ulcers", "Company": "Genaera (Plymouth, PA)", "Stage of Development": "Phase III(Failure)", "Comments": "Drug was refused FDA approval, on the basis that is was no more effective than conventional antibiotics. In part due to the high rate (75%) of spontaneous resolution of disease in controls", "Clinical Trials": ["NCT00563394", "NCT00563433", "NCT01590758", "NCT01594762"]}], "Patent Information": [], "Sequence Information": {"SPADE ID": "SPADE_UN_11329", "Peptide Name": "MSI-78(Pexiganan, Locilex)", "Sequence": "GXGKFLKKAKKFGKAFVKLLKK", "Source": "A broad-spectrum synthetic analogue of the African frog peptide magainin.", "Target Organism": "Gram-positive bacteria:\nStaphylococcus aureus ATCC 29213 (MIC=8-16 μg/ml), Staphylococcus aureus ATCC 33591 (methicillin resistant) (MIC=16-32 μg/ml), Staphylococcus epidermidis ATCC 12228 (MIC=2-4 μg/ml), Enterococcus faecium ATCC 51559 (vancomycin resistant) (MIC=8 μg/ml), Enterococcus faecalis ATCC 29212 (MIC=64 μg/ml), Group A Streptococcus ATCC 49399 (MIC=4 μg/ml), Streptococcus pneumoniae ATCC 49619 (MIC=32 μg/ml), Streptococcus bovis ATCC 49133 (MIC=4 μg/ml), Bacillus cereus ATCC 11778 (MIC=8 μg/ml), Micrococcus luteus ATCC 4698 (MIC=2 μg/ml), Corynebacterium group A ATCC 49676 (MIC=2-4 μg/ml);\nGram-negative bacteria:\nEscherichia coli ATCC 25922 (MIC=8-16 μg/ml), Enterobacter cloacae ATCC 35030 (MIC=8 μg/ml), Proteus mirabilis ATCC 29245 (MIC>256 μg/ml), Serratia marcescens ATCC 8100 (MIC>256 μg/ml), Helicobacter pylori ATCC 43504 (MIC=2 μg/ml), Haemophilus influenzae ATCC 49247 (MIC=8 μg/ml), Pseudomonas aeruginosa ATCC 27853 (MIC=8-16 μg/ml), Bacteroides fragilis ATCC 90028 (MIC=2-4 μg/ml), eroides thetaiotaomicron ATCC 29741 (MIC=2-4 μg/ml), Clostridium difficile ATCC 43255 (MIC=4 μg/ml), Propionibacterium acnes ATCC 29399 (MIC=8 μg/ml), Veillonella parvula ATCC 10790 (MIC=8 μg/ml).", "Reference": ["In vitro antibacterial properties of pexiganan, an analog of magainin. Antimicrob. Agents Chemother(1999).(PMID:10103181)", "Pexiganan acetate. Drugs (1998)", "Potential of immunomodulatory host defense peptides as novel anti-infectives.Trends in Biotechnology(2009).(PMID:19683819)"], "Biological Activity": ["Antibacterial"], "Frequent Amino Acids": "KFG", "Absent Amino Acids": "CDEHIMNOPQRSTUWY", "Basic Residues": 9, "Acidic Residues": 0, "Hydrophobic Residues": 9, "Polar Residues": 12, "Positive Residues": 9, "Negative Residues": 0, "Similar Sequences": [{"SPADE_ID": "SPADE_N_10796", "Similarity": 1.0, "Sequence": "GKFLKKAKKFGK"}, {"SPADE_ID": "SPADE_UN_29934", "Similarity": 1.0, "Sequence": "GKFLKKAKKFGK"}, {"SPADE_ID": "SPADE_N_10797", "Similarity": 1.0, "Sequence": "KFLKKAKKFGKA"}]}}}